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STUDY QUESTION: What is the recommended management for women and transgender men with regards to fertility preservation
(FP), based on the best available evidence in the literature?
SUMMARY ANSWER: The ESHRE Guideline on Female Fertility Preservation makes 78 recommendations on organization of care,
information provision and support, pre-FP assessment, FP interventions and after treatment care. Ongoing developments in FP are
also discussed.
WHAT IS KNOWN ALREADY: The field of FP has grown hugely in the last two decades, driven by the increasing recognition of the
importance of potential loss of fertility as a significant effect of the treatment of cancer and other serious diseases, and the development of
the enabling technologies of oocyte vitrification and ovarian tissue cryopreservation (OTC) for subsequent autografting. This has led to the
widespread, though uneven, provision of FP for young women.
STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the structured methodology for development of
ESHRE guidelines. After formulation of key questions by a group of experts, literature searches and assessments were performed. Papers
published up to 1 November 2019 and written in English were included in the review.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on the collected evidence, recommendations were formulated and
discussed until consensus was reached within the guideline group. A stakeholder review was organized after finalization of the draft. The
final version was approved by the guideline group and the ESHRE Executive Committee.
MAIN RESULTS AND THE ROLE OF CHANCE: This guideline aims to help providers meet a growing demand for FP options by
diverse groups of patients, including those diagnosed with cancer undergoing gonadotoxic treatments, with benign diseases undergoing
gonadotoxic treatments or those with a genetic condition predisposing to premature ovarian insufficiency, transgender men (assigned
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female at birth), and women requesting oocyte cryopreservation for age-related fertility loss.
The guideline makes 78 recommendations on information provision and support, pre-FP assessment, FP interventions and after treatment
care, including 50 evidence-based recommendations—of which 31 were formulated as strong recommendations and 19 as weak—25
good practice points and 3 research only recommendations. Of the evidence-based recommendations, 1 was supported by high-quality ev-
idence, 3 by moderate-quality evidence, 17 by low-quality evidence and 29 by very low-quality evidence. To support future research in the
field of female FP, a list of research recommendations is provided.
LIMITATIONS, REASONS FOR CAUTION: Most interventions included are not well studied in FP patients. As some interventions,
e.g. oocyte and embryo cryopreservation, are well established for treatment of infertility, technical aspects, feasibility and outcomes can be
extrapolated. For other interventions, such as OTC and IVM, more evidence is required, specifically pregnancy outcomes after applying
these techniques for FP patients. Such future studies may require the current recommendations to be revised.
WIDER IMPLICATIONS OF THE FINDINGS: The guideline provides clinicians with clear advice on best practice in female FP, based
on the best evidence currently available. In addition, a list of research recommendations is provided to stimulate further studies in FP.
STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed and funded by ESHRE, covering expenses associated
with the guideline meetings, with the literature searches and with the dissemination of the guideline. The guideline group members did not
receive payment. R.A.A. reports personal fees and non-financial support from Roche Diagnostics, personal fees from Ferring
Pharmaceuticals, IBSA and Merck Serono, outside the submitted work; D.B. reports grants from Merck Serono and Goodlife, outside the
submitted work; I.D. reports consulting fees from Roche and speaker’s fees from Novartis; M.L. reports personal fees from Roche,
Novartis, Pfizer, Lilly, Takeda, and Theramex, outside the submitted work. The other authors have no conflicts of interest to declare.
DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the
time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained.
Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical prac-
tice guidelines do not replace the need for application of clinical judgment to each individual presentation, nor variations based on locality and facility type.
ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability
and fitness for a particular use or purpose. (Full disclaimer available at www.eshre.eu/guidelines.)
†ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.
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ervation / ovarian tissue cryopreservation / ovarian transposition / pregnancy / organization of care
Introduction
The field of fertility preservation (FP) has grown hugely in the last
two decades, driven by the increasing recognition of the impor-
tance of potential loss of fertility as a very important effect of the
treatment of cancer and other serious diseases, and the develop-
ment of the enabling technologies of oocyte vitrification and ovarian
tissue cryopreservation for subsequent autografting. This has led to
the widespread, though uneven, provision of FP for many women
and young girls. The very rapid development of this field in clinical
practice, yet with limited data on outcomes, has led to the need
for the evaluation of the underpinning evidence and the develop-
ment of guidelines to assist practitioners in its safe and effective
implementation.
The guideline focuses on FP options for four populations: (i) post
pubertal women diagnosed with cancer undergoing gonadotoxic
treatments; (ii) post pubertal women with benign diseases undergo-
ing gonadotoxic treatments or with conditions associated with prema-
ture loss of fertility, e.g. Turner syndrome; (iii) transgender men
(assigned female at birth); and (iv) women considering oocyte cryopres-
ervation for age-related fertility loss. In all these four populations, the
guideline also provides recommendations regarding patient selection to
ensure safe and effective care, including during future pregnancy. While
it is recognized that this does not comprehensively include all those re-
quiring FP (notably men, prepubertal girls and boys and transgender
women), it was decided to limit the scope to focus primarily on adult
women.
WHAT DOES THIS MEAN FOR PATIENTS?
Fertility preservation (FP) is a term used for interventions and procedures aiming at preserving the chance of having a baby when your fer-
tility may be damaged by your medical condition or its treatment. FP may be appropriate before undergoing treatments that can affect fer-
tility such as in women diagnosed with cancer or other non-malignant diseases (e.g. lupus, endometriosis and Turner syndrome). FP can
also be considered by transgender men and by women worried about age-related fertility loss.
The current paper summarizes the ESHRE Guideline on FP providing clinicians with evidence-based recommendations on different FP
techniques and how to apply them. These techniques include egg, embryo and ovarian tissue freezing, ovarian transposition and medical
treatment to protect your ovaries. In addition, the guideline also provides recommendations on how to care for, inform and support
patients requiring FP. The full guideline and a patient leaflet are available on https://www.eshre.eu/FFPguideline.

























































































The guideline was developed according to a well-documented meth-
odology that is universal to ESHRE guidelines (Vermeulen et al., 2017)
. The guideline development group (GDG) was composed of past and
present members of the coordination of the Special Interest groups
(SIGs) Fertility Preservation and Quality and Safety in ART, with repre-
sentation of other SIGs (SIG Psychology and counselling, and SIG
Ethics and law), and addition of experts in the field, including oncolo-
gists, a scientist, and patient representatives.
In short, 21 key questions were formulated by the GDG, of which 7
were answered as narrative questions, and 14 as PICO (Patient,
Intervention, Comparison, Outcome) questions. For each PICO ques-
tion, databases (PUBMED/MEDLINE and the Cochrane library) were
searched from inception to 1 November 2019, limited to studies writ-
ten in English. From the literature searches, studies were selected
based on the PICO questions, assessed for quality and summarized in
evidence tables. GDG meetings were organized where the evidence
and draft recommendations were presented by the assigned GDG
member and discussed until consensus was reached within the group.
Each recommendation was labelled as strong or weak and a grade
was assigned based on the strength of the supporting evidence (High
, Moderate , Low , Very low ).
Good practice points (GPPs) based on clinical expertise were added
where relevant to clarify the recommendations or to provide further
practical advice. ‘Research only’ recommendations were also made,
and those interventions should be applied only within the context of
research, with appropriate precautions and ethical approval.
Strong recommendations should be used as a recommendation to
be applied for most patients, while weak recommendations require
discussion and shared decision-making.
For the narrative questions, a similar literature search was con-
ducted. Collected data were summarized in a narrative summary and
conclusions were formulated.
The guideline draft and an invitation to participate in the stakeholder
review were published on the ESHRE website between 6 May and 17
June 2020. All comments were processed by the GDG, either by
adapting the content of the guideline and/or by replying to the re-
viewer. The review process was summarized in the review report
which is published on the ESHRE website (www.eshre.eu/Guidelines).
Overall, 71.5% of the 231 comments resulted in an adaptation or cor-
rection in the guideline text.
This guideline will be considered for update 4 years after publication,
with an intermediate assessment of the need for updating 2 years after
publication.
Results
Key questions and recommendations
The current document summarizes all the key questions and the rec-
ommendations from the guideline ‘Female Fertility Preservation’.
Further background information and the supporting evidence for each
recommendation can be found in the full version of the guideline avail-
able at https://www.eshre.eu/FFPguideline.
Organization of care
How should the care for women undergoing fertility preservation be
organized?
A team approach to care for women undergoing FP is advocated in
the guideline. To support implementation, the following suggestions
were formulated (Figure 1).
There should be agreement within an FP service for who is re-
sponsible for all issues, including agreement on referral pathways,
availability of standard forms for diagnosis, intended therapy, time
intervals and a check whether FP counselling has been offered and
has taken place. For FP treatment, a member of the FP team should
be responsible for discussing any proposed treatment with the clini-
cal care team before treatment initiation. Documentation and regis-
tration should be organized; all relevant medical information should
be documented in the patients’ medical records, all patients under-
going FP should have been counselled about the legal and financial
consequences and must have given written informed consent and
accurate supporting documentation, especially about the gametes/
embryos/tissue stored, is essential as storage may last for many
years.
A direct link between the clinical care team and the FP team, pref-
erably in multidisciplinary team meetings, is recommended. In addition,
identification of a key individual (the ‘coordinator’) in clinical care
teams is advisable to facilitate patients of reproductive age meeting
with the FP team. Psychological support/counselling should be avail-
able to all patients considering FP, and specific support for particular
patient groups may be required.
Expanding access to FP options is also important in the organization
of FP care. The guideline group advocates improving (i) public aware-
ness of fertility and of factors that may have negative effects on it; (ii)
oncologists’ awareness of FP options; (iii) referral pathways; and (iv)
availability of different FP procedures. With regard to these items, spe-
cific attention should be given to FP care for specific patient groups,
such as adolescents and transgender men.
The key organizational features for establishing an FP program are
summarized in Figure 2.
With regard to availability of FP interventions and storage of re-
productive material, a survey was conducted to collect national leg-
islative information in European countries, while recognizing that this
is a constantly changing area. It was concluded that FP is available in
most but not all European countries; thus, specialists should be
aware of their national legislative and regulatory situation. This gen-
erally supportive legislative environment applies to patients with
cancer and benign diseases, and mostly to transgender men.
Provision of financial support is less widespread. This may reflect
the rapidly developing nature of some FP procedures, and the ongo-
ing change in their status from experimental towards being part of
established care. With regards to the duration of storage of repro-
ductive materials, regulations are very variable across Europe. Some
countries also have different storage regulations for different materi-
als. While a duration of storage is often applied, this may be supple-
mented by an upper age limit for use. Given the young age at which
FP may occur, the often short allowable duration of storage (5–
10 years in many countries) is inappropriate, and legislation should
focus more on a maximum age of use.
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..Information needs and provision
What information needs to be provided to
women at risk of infertility?
How should information on fertility preservation
options be provided to patients?
The full guideline includes a table of decision aids that are currently
available for FP interventions. A checklist for clinicians to cover the
information needs of patients undergoing FP counselling (for the four
different indications) is included as Supplementary data I.
Figure 1. Model of care for patients eligible for fertility preservation (FP).
Clinicians should provide information to patients regarding (i) im-
pact of cancer, other diseases and their treatments on reproductive
function; (ii) impact of cancer, other diseases and their treatment
on fertility, (iii) FP options; (iv) issues related to cryopreservation
storage after FP, (v) infertility and fertility treatments; (vi) pregnancy
after gonadotoxic treatment or underlying condition; and (vii) other
childbearing and parenting options (Peate et al., 2009; Goossens




Information provided should be specific to the patients’ needs. GPP
Age-specific information and counselling should be provided for
adolescents and young adults.
GPP
It is recommended to provide decision aids to patients who are




Healthcare professionals may consider the use of a checklist for












.Is there a benefit of psychological support and
counselling and are there particular groups that
would benefit from it?
The multidisciplinary FP team counselling FP patients should be aware
that maladaptive psychological processes and past psychopathology
are risk factors for psychological distress during FP decision. It is rec-
ommended that patients at risk are referred for psychological support
when needed.
Figure 2. Checklist for a high-quality fertility preservation (FP) program.
It is recommended that patients are offered psychological sup-
port and counselling when dealing with FP decisions, although
the extent of the clinical benefit has not been studied (Chiavari
et al., 2015; Greenwood et al., 2018; Logan et al., 2018;
Anazodo et al., 2019).
STRONG

Clinicians may consider referring FP patients who present risk fac-
tors for psychological distress for psychological support and counsel-
ling (Lawson et al., 2014; O’Hea et al., 2016; Shah et al., 2016;
Witcomb et al., 2018; Logan et al., 2019).
WEAK






Patient selection and pre-FP assessment
Which criteria can be used to select patients for
fertility preservation?
A checklist for patient assessment and selection for FP is presented in
Figure 3.
Which factors should be taken into account when
estimating the individual risk of gonadotoxicity
for a patient?
An overview of factors that increase the risk of gonadotoxicity, and of
factors where evidence is not yet available in presented in Figure 4.
Is it relevant to do ovarian reserve testing, and
for whom?
Fertility preservation interventions
Which options are available for fertility preservation in women—
emergency and non-emergency?
Fertility can be preserved through several procedures, including cryo-
preservation of oocytes, embryos or ovarian tissue, and potentially
medical and surgical methods of protection (see Figure 5). Since the
development of vitrification, oocyte cryopreservation is the method of
choice for women undergoing treatment for age-related fertility loss,
and for most women undergoing FP for medical indications. Embryo
cryopreservation is even more widely available and long-established
part of assisted reproduction, but the necessity for joint legal owner-
ship with the male partner is an important consideration that may re-
sult in difficulties later on. Ovarian tissue cryopreservation (OTC) is an
important option either through choice, or if there is insufficient time
for ovarian stimulation. In vitro oocyte maturation (IVM) can also be
considered, and in some cases, there may be a possibility of combining
different approaches.
Protection of the ovary against the effects of treatment would be an
ideal approach. Options include GnRH agonists (mostly investigated in
women with breast cancer) and ovarian transposition in women
scheduled for pelvic radiotherapy.
Patients require an individual assessment of the indications and
risks prior to FP interventions.
GPP
A multidisciplinary team is recommended to have an accurate
assessment of risks.
GPP
For women with overt premature ovarian insufficiency (POI), FP
is not recommended.
GPP
The risk of gonadotoxicity should be assessed in all patients un-
dergoing gonadotoxic treatments.
GPP
To estimate the individual risk of gonadotoxicity, the
characteristics of the proposed treatment, the patient and the
disease should be considered (Tauchmanova et al., 2003;
Bernhard et al., 2007; Anderson and Cameron, 2011; Abusief
et al., 2012; Lawrenz et al., 2012; van der Kaaij et al., 2012;
Valentini et al., 2013; Akhtar et al., 2015; Ruddy et al., 2015;
Lekovich et al., 2016; Silva et al., 2016; Freour et al., 2017;
Lambertini et al., 2017, 2019a,d; Dezellus et al., 2017a;
Anderson et al., 2017b,c).
STRONG

For predicting high and low response to ovarian stimulation, use
of either antral follicle count (AFC) or anti-Müllerian hormone
(AMH) is recommended over other ovarian reserve tests.
STRONG

Assessment of pre-treatment ovarian function, in particular
through AMH levels, in premenopausal women with a diagnosis
of breast cancer or haematological malignancy is recommended
to predict post-treatment recovery of ovarian function
(Anderson et al., 2013; Dillon et al., 2013; Peigne and Decanter,
2014; Su et al., 2014; Silva et al., 2016; Dezellus et al., 2017b).
STRONG

Pre-treatment AMH levels should not be used as an indicator of
post-treatment fertility (Hamy et al., 2016).
WEAK

When estimating the risk of post-treatment POI, age, proposed
gonadotoxic treatment type and dose, as well as pre-treatment
AMH levels, should be taken into consideration (Anderson et al.,
2013; Su et al., 2014; Barnabei et al., 2015).
STRONG

Pre-treatment ovarian reserve testing could be performed in
women with other malignancies, as testing is likely to be of high
relevance based on indirect evidence from breast and haemato-
logical cancers (Dillon et al., 2013).
WEAK

The relevance of ovarian reserve testing to help guide FP options
or treatment decisions in systemic lupus erythematosus patients
is low (Morel et al., 2013).
WEAK

The relevance of ovarian testing to help guide FP options or
treatment decisions in endometriosis patients remains inconclu-
sive (Reinblatt et al., 2011; Benaglia et al., 2013; Ashrafi et al.,
2019; Zhou et al., 2019).
WEAK

Clinicians should be aware that in patients with endometriosis,
the involvement of the ovaries and the radicality of surgery influ-
ence ovarian reserve as measured by AMH levels, but that its
relevance to future fertility is unclear.
GPP
For women with reduced ovarian reserve (Bologna criteria,
AMH <0.5 ng/ml), advice needs to be individualized and the
value of FP is unclear.
GPP
Figure 3. Checklist for patients’ assessment and selection
for fertility preservation (FP) interventions (adapted from
Wallace et al. (2012)).





How should ovarian stimulation be performed in
cancer patients undergoing FP treatment?
Is oocyte cryopreservation effective and safe for
FP?
Figure 4. Summary of factors to be considered when estimating the risk of gonadotoxicity.
For ovarian stimulation in women seeking FP for medical rea-
sons, the GnRH antagonist protocol is recommended for its fea-
sibility in urgent situations, short time and safety reasons (The
ESHRE Guideline Group on Ovarian Stimulation et al., 2020).
STRONG

For patients requiring ovarian stimulation where there is a lack
of urgency, the use of a long protocol may also be appropriate




In urgent FP cycles, random-start ovarian stimulation is an option
(Marklund et al., 2020; The ESHRE Guideline Group on Ovarian
Stimulation et al., 2020).
WEAK

Double stimulation can be considered for urgent FP cycles (The
ESHRE Guideline Group on Ovarian Stimulation et al., 2020;
Vaiarelli et al., 2020).
WEAK

In ovarian stimulation for FP in oestrogen-sensitive diseases the
concomitant use of anti-oestrogen therapy, such as letrozole, is
probably recommended.
GPP
For ovarian stimulation in transgender men aiming at oocyte
cryopreservation, GnRH antagonist protocols can be considered
as they have been shown to be feasible and with numbers of
oocytes retrieved comparable to those obtained in cisgender




How should ovarian stimulation be performed in
transgender men undergoing FP treatment?
For transgender men, the addition of letrozole to the antagonist
protocol can be considered as it may enhance treatment adher-
ence by reducing oestrogenic symptoms (Armuand et al., 2017).
GPP
Oocyte cryopreservation should be offered as an established op-
tion for FP (Rienzi et al., 2012; Cobo et al., 2013; Druckenmiller
et al., 2016; Massarotti et al., 2017; Cobo et al., 2018;
Rodriguez-Wallberg et al., 2019b).
STRONG

Women with a partner should be offered the option to cryopre-
serve unfertilized oocytes or to split the oocytes to attempt
both embryo and oocyte cryopreservation.
GPP
Women should be informed of accurate, centre-specific exper-
tise and live birth rates. They should also be informed that suc-
cess rates after cryopreservation of oocytes at the time of a
cancer diagnosis may be lower than in women without cancer.
GPP






..Oocyte cryopreservation for age-related fertility
loss
Is embryo cryopreservation effective and safe for
fertility preservation?
Should ovarian tissue cryopreservation be used
for FP?
Figure 5. Schematic overview of the options for female fertility preservation (FP). Adapted from (Anderson et al., 2015) .
Women considering oocyte cryopreservation for age-related
fertility loss should be fully informed regarding the success rates,
risks, benefits, costs and the possible long-term consequences,
both in terms of physical and psychological health (Rienzi et al.,
2012; Cobo et al., 2013; Druckenmiller et al., 2016; Massarotti
et al., 2017; Cobo et al., 2018; Ethics Committee of the
American Society for Reproductive Medicine, 2018; Rodriguez-
Wallberg et al., 2019b; Anderson et al., 2020).
STRONG

Suitability should be determined on a case-by-case basis. GPP
Embryo cryopreservation is an established option for FP
(Dolmans et al., 2005; Barcroft et al., 2013; Courbiere et al.,
2013; Debrock et al., 2015; Dolmans et al., 2015; Rienzi et al.,
2017; Alvarez and Ramanathan, 2018; Cobo et al., 2018;
Rodriguez-Wallberg et al., 2019a).
STRONG

Women should be informed about the risk of losing reproductive
autonomy and possible issues with ownership of stored embryos.
GPP
Women should be informed of accurate, centre-specific exper-
tise and live birth rates. They should also be informed that suc-
cess rates after cryopreservation of embryos at the time of a
cancer diagnosis may be lower than in women without cancer.
GPP
It is recommended to offer OTC in patients undergoing moder-
ate/high-risk gonadotoxic treatment where oocyte/embryo
cryopreservation is not feasible, or at patient preference
(Pacheco and Oktay, 2017; Gellert et al., 2018).
STRONG

OTC should probably not be offered to patients with low ovarian
reserve (AMH< 0.5 ng/ml and AFC< 5) or advanced age consider-
ing the unfavourable risk/benefit. Current evidence suggest that the
efficiency of OTC procedure is questionable above 36 years of age
(Paradisi et al., 2016; Diaz-Garcia et al., 2018; Gellert et al., 2018).
WEAK

The GDG considers that OTC is an innovative method for ovar-
ian function and fertility preservation in post pubertal women.
GPP
Patients who have already received low gonadotoxic treatment
or a previous course of chemotherapy, can be offered OTC as
FP option (Poirot et al., 2019).
WEAK

Ovarian stimulation can be performed immediately after OTC




OTC at the time of oocyte pick-up after ovarian stimulation
should not be performed unless in a research context.
RESEARCH
ONLY
Ovarian transposition can be performed at the same time as
OTC in patients who will receive pelvic irradiation.
GPP
OTC is not recommended as the primary FP procedure in trans-
gender men but can be proposed as an experimental option
when ovaries are removed during gender reassignment surgery.
GPP







Should vitrification versus slow-freezing be used
for OTC for FP?
Which safety issues should be considered when
replacing ovarian tissue?
Should IVM be used for FP?
Should GnRH agonists be used for ovarian
protection in patients undergoing gonadotoxic
treatment?
Should transposition of ovaries be used for
ovarian protection?
After treatment care
How should patients be re-assessed before use of
stored material?
Information on patient re-assessment before attempting pregnancy
(with or without the use of stored material) is summarized in Figure 6.
With regards to pre-conception counselling, a checklist was prepared
outlining the reproductive options after FP for cancer patients and for
transgender men (Supplementary data II).
The slow-freezing protocol should be used for OTC as it is well-
established and considered as standard (Fabbri et al., 2016;
Dalman et al., 2017; Shi et al., 2017).
STRONG





For OTT, a one-step laparoscopy procedure should be per-
formed as it is considered safe without causing additional surgical
risk (Schmidt et al., 2011; Beckmann et al., 2017, 2018).
STRONG

OTT at the orthotopic site is recommended to restore fertility
(Beckmann et al., 2017; Gellert et al., 2018).
STRONG

The decision to perform OTT in oncological patients requires a
multidisciplinary approach.
GPP
It is recommended to evaluate the presence of residual neoplas-
tic cells in the ovarian cortex (and in the residual medulla when
available) using appropriate techniques in all cancer survivors be-
fore OTT and patients should be informed about this risk (Abir
et al., 2010; Bittinger et al., 2011; Fabbri et al., 2012; Greve
et al., 2012; Bastings et al., 2013; Dolmans et al., 2013, 2016;
Jahnukainen et al., 2013; Luyckx et al., 2013; Bockstaele et al.,
2015; Rodriguez-Iglesias et al., 2015; Kristensen et al., 2017;
Anderson et al., 2017d; Andersen et al., 2018; Gellert et al.,
2018; Masciangelo et al., 2018; Shapira et al., 2018).
STRONG

OTT is not recommended in cases where the ovary is involved in
the malignancy (Kristensen et al., 2017; Masciangelo et al., 2018).
STRONG

OTT and pregnancy can be considered in hormone-sensitive
tumours such as endometrial cancer treated by fertility-sparing
strategy or breast cancer, after complete remission of the dis-
ease (Lambertini et al., 2018a).
STRONG

There appears to be no increased risk of congenital abnormali-
ties for children born after OTT (Pacheco and Oktay, 2017;
Gellert et al., 2018).
WEAK

Long-term risks in human are considered to be low but a long-
term follow-up of patients after OTT is recommended.
GPP
OTT can be offered in BRCA patients, as an alternative when
egg or embryo freezing is not feasible, but the ovarian tissue
must be completely removed after subsequent pregnancy
(Lambertini et al., 2018a, 2019b).
WEAK

OTC/ovarian tissue transplantation (OTT) can be considered in
patients with POI-associated genetic and chromosomal disor-
ders but requires genetic counselling and should be performed
within a research protocol.
RESEARCH
ONLY
IVM should be regarded as an innovative FP procedure (Moria
et al., 2011; Creux et al., 2018; Grynberg et al., 2019).
STRONG

IVM requires specific expertise and should only be performed
when oocyte cryopreservation is required but ovarian stimula-
tion not feasible.
GPP




GnRH agonists during chemotherapy should be offered as an op-
tion for ovarian function protection in premenopausal breast
cancer patients receiving chemotherapy; however, limited evi-
dence exists on their protective effect on the ovarian reserve




In women with breast cancer, GnRH agonists during chemother-
apy should not be considered an option for FP instead of cryo-
preservation techniques (Lambertini et al., 2015, 2018c).
STRONG

In malignancies other than breast cancer, GnRH agonists should
not be routinely offered as an option for ovarian function protec-
tion and FP without discussion of the uncertainty about
its benefit (Gilani et al., 2007; Senra et al., 2018).
STRONG

GnRH agonists during chemotherapy may be considered as an
option for ovarian function protection in premenopausal patients
with autoimmune diseases receiving cyclophosphamide.
However, it should be acknowledged that limited data are avail-
able in this setting (Ben-Aharon et al., 2010; Marder et al., 2012;
Brunner et al., 2015).
WEAK

GnRH agonists should not be considered an equivalent or alter-
native option for FP but can be offered after cryopreservation
techniques or when they are not possible.
GPP
Before the use of stored material, fitness for pregnancy should
be thoroughly assessed, taking into account treatment late
effects, the age of the patient and the interval since treatment.
STRONG

The need for psychological counselling, pre-conception counsel-
ling and fertility treatment counselling should be considered for
all patients. Local guidelines for counselling should be followed.
GPP
Where pelvic radiotherapy without chemotherapy is planned,
women may be offered ovarian transposition with the aim to
prevent POI (Gubbala et al., 2014; Hoekman et al., 2019).
WEAK

Women with reduced ovarian reserve and women at risk of hav-
ing ovarian metastases are inappropriate candidates for ovarian
transposition.
GPP























































































.What is the effect of previous gonadotoxic
treatments and underlying conditions on
obstetric outcomes?
With regards to obstetric outcomes after oocyte cryopreservation for
age-related fertility loss, it has been shown that there are risks of due
to older age at pregnancy, which increase after the age of 45 (Aoyama
et al., 2019). More research is needed on the number of women who
return to use their frozen oocytes, pregnancy complications, and live
birth rates in these women.
Future FP interventions
What are ongoing developments with regards to FP?
To increase the spectrum of FP options, innovative technologies and
novel in vitro avenues are continually being developed. This includes
technologies involving transplantation into the patient, such as trans-
plantation of the whole ovary after cryopreservation and procedures
to optimize the use of transplanted ovarian cortex tissue, such as
in vitro activation, processes to reduce ischaemia by promoting re-
vascularization, techniques to eliminate residual malignant cells,
methods for transplantation of follicles isolated from ovarian cortex
tissue as bioprosthetic ovaries, and methods for transplantation of
isolated cells into the remaining (gonadotoxic-exposed) ovary.
Another line of research focuses on technologies that do not involve
transplantation, such as in vitro matured oocytes from cultured ovar-
ian cortex tissue, in vitro matured oocytes from primordial follicles
isolated from ovarian cortex tissue and in vitro matured oocytes
from cells isolated from the ovary. In addition, research is con-
ducted in the use of in vitro matured oocytes from induced pluripo-
tent stem cells (in vitro gametogenesis) or from mesenchymal
stromal cells. Treatments to prevent gonadotoxic-induced POI have
been recently reviewed (Spears et al., 2019).
Regarding future FP interventions, the GDG formulated the fol-
lowing conclusion: It is important to stress that emerging technolo-
gies, however promising, need to be followed by rigorous clinical
trials, ensuring internationally accepted standards, to demonstrate
efficacy and safety before they can be offered as medical treatment.
Moreover, a scientific-medical consensus is required regarding safety
and functional criteria that needs to be achieved before considering
clinical use of in vitro-derived human oocytes. In this regard, a socie-
tal debate on the ethical issues and what emerging technologies may
be considered acceptable for human reproductive purposes is
recommended.
Discussion
The current paper summarizes the 78 recommendations on informa-
tion provision and support, pre-FP assessment, FP interventions and af-
ter treatment care from the ESHRE Guideline on ‘Female Fertility
Preservation’. This Guideline covers all aspects of FP on four different
patient populations, specifically cancer patients, patients with benign
diseases, transgender men and women requesting FP for age-related
fertility loss, and was written by a multidisciplinary group with gynae-
cologists and fertility specialists, oncologists, a psychologist, a bioethi-
cist, an embryologist, a scientist, and patient representatives.
According to the World Health Organization, individuals and cou-
ples have the right to decide the number, timing and spacing of their
children (https://www.who.int/news-room/fact-sheets/detail/infertil
ity). FP can be considered one option in preventing infertility and an
important part of realizing the right to have a family. The importance
of FP has also been demonstrated at the start of the COVID-19 pan-
demic, when ESHRE recommended not starting fertility treatments
with the exception of treatments for FP. It has been shown that al-
though most fertility treatments were suspended, FP interventions
were continued in most centres throughout Europe (Vermeulen et al.,
2020).
Notwithstanding the importance and relevance of FP, research data
on many aspects are scarce. As a basis for the current guideline, a
broad and formal literature review was conducted. Few relevant RCTs
have been performed, with evidence for most interventions deriving
from case series. Research gaps were detected in several areas, and
these are documented in a list of recommendations for further re-
search (Supplementary data III). Although the literature searches fo-
cused on the four patient populations separately, most studies
Preconception counselling and appropriate obstetric monitoring
is recommended in women intending to become pregnant after
gonadotoxic treatments (Fossa et al., 2005; Madanat-Harjuoja




An interval of at least 1 year following chemotherapy completion
is suggested before attempting a pregnancy in order to reduce
the risk of pregnancy complications (Hartnett et al., 2018).
STRONG

Radiotherapy to a field that included the uterus increases the
risk of pregnancy complications; this risk is age (higher at prepu-
bertal ages) and dose dependent. These pregnancies should be
treated as high risk and managed in a centre with advanced ma-
ternity services (Sanders et al., 1996; Critchley and Wallace,
2005; Signorello et al., 2010; Teh et al., 2014; Tarin et al., 2016;
van de Loo et al., 2019).
STRONG

After completion of the recommended treatment, pregnancy is
safe in women who have survived breast cancer. This is indepen-
dent of oestrogen receptor status of the tumour (Hartman and
Eslick, 2016; Sun et al., 2018; Lambertini et al., 2018b; Lee et al.,
2019; Schuurman et al., 2019).
STRONG

Pregnancy after treatment for breast cancer should be closely
monitored, as there is an increased risk of preterm birth and low
birth weight. Patients should be informed about these risks
(Hartman and Eslick, 2016; Sun et al., 2018; Lee et al., 2019;
Schuurman et al., 2019; Lambertini et al., 2019c).
STRONG

Reliable non-hormonal contraception is mandatory during ta-
moxifen treatment. It is recommended to stop tamoxifen for at
least 3 months before attempting pregnancy.
GPP
Women with endometrial cancer should be followed up for
high-risk pregnancy and monitored by an oncologist due to the
risk of relapse (Chao et al., 2011; Park et al., 2013).
STRONG

The risk of preterm birth is increased after treatment for early
cervical cancer and these pregnancies should be treated as high
risk and managed in a centre with advanced maternity services
(Bentivegna et al., 2016; Kyrgiou et al., 2017; Zhang et al., 2017).
STRONG

Women previously treated for cancer require individual assess-
ment of their obstetric risks and potential additional obstetric
surveillance (Longhi et al., 2000; do Rosario et al., 2006; Haggar
et al., 2013; Marklund et al., 2018).
STRONG

Healthcare professionals should have a high level of awareness
of the risk of depression and increased dysphoria during and af-
ter pregnancy care for transgender men (Light et al., 2014;
Obedin-Maliver and Makadon, 2016; Brandt et al., 2019).
WEAK











































included in the guideline reported on women with cancer, mostly
breast cancer, with very few studies on FP in benign diseases, and
even fewer on FP in transgender men and in women requesting FP for
age-related fertility loss. For the latter patient groups, most reports fo-
cus on feasibility, acceptability and ethical considerations, rather than
efficacy, efficiency and safety. To advance the field of female FP, more
research is needed on the efficacy and safety of both established and
newer techniques with a focus on achievement of live birth, but also
on patient preferences and indications for FP. Indeed, one key aspect
of the provision of FP is the need to widen access, while offering it to
appropriately selected patients with a relevant indication. The variable
provision of FP interventions deprives some women from having a
family. However, applying FP to all patients undergoing gonadotoxic
treatment, even with limited gonadotoxicity, will result in large
amounts of stored but unused reproductive cells and tissue, creating
unnecessary burden and costs for some patients involved and for
health services. The risk of gonadotoxicity can be estimated or quanti-
fied in those patients receiving specific treatments that have been stud-
ied in sufficient detail, albeit generally with ovarian reserve testing
which has very limited value for predicting future fertility. For many
patients, the risk and benefits of FP interventions require multidiscipli-
nary discussion and decision-making with regards to FP. New targeted
treatments in oncology including immunotherapy largely have unknown
gonadotoxicity (Lambertini et al., 2020). Providing appropriate informa-
tion to patients and supporting their decision-making is crucial, both
on whether to proceed with FP, and when it has become time to
attempt pregnancy. Patient information leaflets summarizing the guide-
line’s most relevant information for patients are available and can be
used as a template, and links to decision aids are provided.
Despite the limitations of guidelines in general, and the limitations in
the evidence supporting the current guideline, the guideline group is
confident that this document will help best practice in female FP.
Supplementary data
Supplementary data are available at Human Reproduction Open online.
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